Envista EPS Estimates Rise 11.6% to $0.30, Full-Year $1.36 Outlook
Analysts have raised the quarterly EPS forecast for the dental-products maker to $0.30, a 25% year-over-year increase, driving an 11.6% upward revision in the consensus estimate over the past month. Full-year EPS projections climbed 7.96% to $1.36 as covering analysts issued five upward revisions.
1. Estimate Revisions Trend
Analysts issued three upward revisions to next-quarter EPS over the past 30 days with zero downgrades, lifting the consensus estimate by 11.64%. For the full year, five upward revisions have driven a 7.96% increase in the consensus forecast, reflecting growing optimism on earnings prospects.
2. Quarterly Forecast
The consensus EPS forecast for the current quarter stands at $0.30, representing a 25% year-over-year gain as the company benefits from robust dental products demand and margin improvements.
3. Full-Year Outlook
Full-year EPS projections have been raised to $1.36, up 14.3% versus the prior year, supported by operational efficiencies and sustained end-market growth in its core dental segment.
4. Stock Performance Impact
These estimate revisions and the upgrade to a Zacks Rank #1 (Strong Buy) have coincided with a 23.2% stock rally over the past four weeks, suggesting further upside potential as investor confidence strengthens.